Improvement of sleep and melatonin in children with autism spectrum disorder after β‐1,3/1,6‐glucan consumption: An open‐label prospective pilot clinical study
Abstract Introduction Poor sleep quality is a major problem in patients with autism spectrum disorder (ASD), and is attributed to low melatonin levels. Melatonin supplementation is recommended; however, its effectiveness varies. β‐Glucans have previously been shown to improve melatonin levels in ani...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-09-01
|
| Series: | Brain and Behavior |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/brb3.2750 |
| _version_ | 1798033581302349824 |
|---|---|
| author | Kadalraja Raghavan Vidyasagar Devaprasad Dedeepiya Ramesh Shankar Kandaswamy Mangaleswaran Balamurugan Nobunao Ikewaki Tohru Sonoda Gene Kurosawa Masaru Iwasaki Senthilkumar Preethy Samuel JK Abraham |
| author_facet | Kadalraja Raghavan Vidyasagar Devaprasad Dedeepiya Ramesh Shankar Kandaswamy Mangaleswaran Balamurugan Nobunao Ikewaki Tohru Sonoda Gene Kurosawa Masaru Iwasaki Senthilkumar Preethy Samuel JK Abraham |
| author_sort | Kadalraja Raghavan |
| collection | DOAJ |
| description | Abstract Introduction Poor sleep quality is a major problem in patients with autism spectrum disorder (ASD), and is attributed to low melatonin levels. Melatonin supplementation is recommended; however, its effectiveness varies. β‐Glucans have previously been shown to improve melatonin levels in animal studies. Herein, we examined the effectiveness of Aureobasidium pullulans (Nichi Glucan), a species of black yeast that contains beta‐1,3/1,6‐glucan, in a pilot study of children with ASD. Methods Thirteen children (age, 2.5–13 years) with ASD were recruited for the study. The control group consisted of four patients (Gr. 1), while nine patients were classified into the treatment group (Gr. 2). Gr. 2 received 1 g of Nichi Glucan along with conventional therapy, whereas the Gr. 1 (control) patients received conventional therapy alone for 90 days. Serum melatonin levels and sleep patterns, assessed using a subjective questionnaire, were evaluated before and after treatment. Results In Gr. 2, the average serum melatonin level increased from 238.85 ng/L preintervention to 394.72 ng/L postintervention. Eight of nine participants (88%) in Gr. 2 showed improvements in sleep pattern and quality, while no improvement was observed in the participants in Gr. 1. Conclusion The consumption of Nichi Glucan for 90 days resulted in visible improvement in sleep quality, sleep pattern, and serum melatonin levels, which was reported for the first time by our study. A larger multicenter study is required to validate our findings. |
| first_indexed | 2024-04-11T20:31:47Z |
| format | Article |
| id | doaj.art-a3dd354d70684f05aa1f22dda11962e5 |
| institution | Directory Open Access Journal |
| issn | 2162-3279 |
| language | English |
| last_indexed | 2024-04-11T20:31:47Z |
| publishDate | 2022-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Brain and Behavior |
| spelling | doaj.art-a3dd354d70684f05aa1f22dda11962e52022-12-22T04:04:29ZengWileyBrain and Behavior2162-32792022-09-01129n/an/a10.1002/brb3.2750Improvement of sleep and melatonin in children with autism spectrum disorder after β‐1,3/1,6‐glucan consumption: An open‐label prospective pilot clinical studyKadalraja Raghavan0Vidyasagar Devaprasad Dedeepiya1Ramesh Shankar Kandaswamy2Mangaleswaran Balamurugan3Nobunao Ikewaki4Tohru Sonoda5Gene Kurosawa6Masaru Iwasaki7Senthilkumar Preethy8Samuel JK Abraham9Department of Paediatric Neurology Kenmax Medical Service Private Limited Madurai IndiaMary‐Yoshio Translational Hexagon (MYTH) Nichi‐In Centre for Regenerative Medicine (NCRM) Chennai IndiaDepartment of Psychiatry Lincolnshire Partnership NHS Foundation Trust Lincoln United KingdomDepartment of Neurosurgery Brain and Spine Hospital Chennai IndiaDepartment of Medical Life Science Kyushu University of Health and Welfare JapanDepartment of Immunology Junsei Educational Institute Nobeoka Miyazaki JapanDepartment of Academic Research Support Promotion Facility, Center for Research Promotion and Support Fujita Health University Aichi JapanCentre for Advancing Clinical Research (CACR) School of Medicine, University of Yamanashi Chuo JapanFujio‐Eiji Academic Terrain (FEAT) Nichi‐In Centre for Regenerative Medicine (NCRM) Chennai IndiaMary‐Yoshio Translational Hexagon (MYTH) Nichi‐In Centre for Regenerative Medicine (NCRM) Chennai IndiaAbstract Introduction Poor sleep quality is a major problem in patients with autism spectrum disorder (ASD), and is attributed to low melatonin levels. Melatonin supplementation is recommended; however, its effectiveness varies. β‐Glucans have previously been shown to improve melatonin levels in animal studies. Herein, we examined the effectiveness of Aureobasidium pullulans (Nichi Glucan), a species of black yeast that contains beta‐1,3/1,6‐glucan, in a pilot study of children with ASD. Methods Thirteen children (age, 2.5–13 years) with ASD were recruited for the study. The control group consisted of four patients (Gr. 1), while nine patients were classified into the treatment group (Gr. 2). Gr. 2 received 1 g of Nichi Glucan along with conventional therapy, whereas the Gr. 1 (control) patients received conventional therapy alone for 90 days. Serum melatonin levels and sleep patterns, assessed using a subjective questionnaire, were evaluated before and after treatment. Results In Gr. 2, the average serum melatonin level increased from 238.85 ng/L preintervention to 394.72 ng/L postintervention. Eight of nine participants (88%) in Gr. 2 showed improvements in sleep pattern and quality, while no improvement was observed in the participants in Gr. 1. Conclusion The consumption of Nichi Glucan for 90 days resulted in visible improvement in sleep quality, sleep pattern, and serum melatonin levels, which was reported for the first time by our study. A larger multicenter study is required to validate our findings.https://doi.org/10.1002/brb3.2750autism spectrum disorder (ASD)beta‐glucanfood supplementmelatoninsleep |
| spellingShingle | Kadalraja Raghavan Vidyasagar Devaprasad Dedeepiya Ramesh Shankar Kandaswamy Mangaleswaran Balamurugan Nobunao Ikewaki Tohru Sonoda Gene Kurosawa Masaru Iwasaki Senthilkumar Preethy Samuel JK Abraham Improvement of sleep and melatonin in children with autism spectrum disorder after β‐1,3/1,6‐glucan consumption: An open‐label prospective pilot clinical study Brain and Behavior autism spectrum disorder (ASD) beta‐glucan food supplement melatonin sleep |
| title | Improvement of sleep and melatonin in children with autism spectrum disorder after β‐1,3/1,6‐glucan consumption: An open‐label prospective pilot clinical study |
| title_full | Improvement of sleep and melatonin in children with autism spectrum disorder after β‐1,3/1,6‐glucan consumption: An open‐label prospective pilot clinical study |
| title_fullStr | Improvement of sleep and melatonin in children with autism spectrum disorder after β‐1,3/1,6‐glucan consumption: An open‐label prospective pilot clinical study |
| title_full_unstemmed | Improvement of sleep and melatonin in children with autism spectrum disorder after β‐1,3/1,6‐glucan consumption: An open‐label prospective pilot clinical study |
| title_short | Improvement of sleep and melatonin in children with autism spectrum disorder after β‐1,3/1,6‐glucan consumption: An open‐label prospective pilot clinical study |
| title_sort | improvement of sleep and melatonin in children with autism spectrum disorder after β 1 3 1 6 glucan consumption an open label prospective pilot clinical study |
| topic | autism spectrum disorder (ASD) beta‐glucan food supplement melatonin sleep |
| url | https://doi.org/10.1002/brb3.2750 |
| work_keys_str_mv | AT kadalrajaraghavan improvementofsleepandmelatonininchildrenwithautismspectrumdisorderafterb1316glucanconsumptionanopenlabelprospectivepilotclinicalstudy AT vidyasagardevaprasaddedeepiya improvementofsleepandmelatonininchildrenwithautismspectrumdisorderafterb1316glucanconsumptionanopenlabelprospectivepilotclinicalstudy AT rameshshankarkandaswamy improvementofsleepandmelatonininchildrenwithautismspectrumdisorderafterb1316glucanconsumptionanopenlabelprospectivepilotclinicalstudy AT mangaleswaranbalamurugan improvementofsleepandmelatonininchildrenwithautismspectrumdisorderafterb1316glucanconsumptionanopenlabelprospectivepilotclinicalstudy AT nobunaoikewaki improvementofsleepandmelatonininchildrenwithautismspectrumdisorderafterb1316glucanconsumptionanopenlabelprospectivepilotclinicalstudy AT tohrusonoda improvementofsleepandmelatonininchildrenwithautismspectrumdisorderafterb1316glucanconsumptionanopenlabelprospectivepilotclinicalstudy AT genekurosawa improvementofsleepandmelatonininchildrenwithautismspectrumdisorderafterb1316glucanconsumptionanopenlabelprospectivepilotclinicalstudy AT masaruiwasaki improvementofsleepandmelatonininchildrenwithautismspectrumdisorderafterb1316glucanconsumptionanopenlabelprospectivepilotclinicalstudy AT senthilkumarpreethy improvementofsleepandmelatonininchildrenwithautismspectrumdisorderafterb1316glucanconsumptionanopenlabelprospectivepilotclinicalstudy AT samueljkabraham improvementofsleepandmelatonininchildrenwithautismspectrumdisorderafterb1316glucanconsumptionanopenlabelprospectivepilotclinicalstudy |